
A legacy that inspires the Future.
From the first guidewire to the first drug-eluting stent, Cordis has led cardiovascular innovation for over 60 years. Today, we're driving the next transformation through internal R&D, the Cordis-X incubator, and strategic acquisitions. Backed by a global footprint, we’re advancing technologies that improve outcomes, prioritize customer needs, and elevate education—reaffirming our commitment to the interventional community. Cordis will Go Beyond to transform cardiovascular care.

Innovating and Delivering New Technologies
Cordis is proud to have completed the acquisition of MedAlliance and its novel SELUTION SLR™ Drug-Eluting Balloon (DEB). Using breakthrough proprietary technology, MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with the SELUTION SLR™ DEB. Cordis and MedAlliance combined are committed to accelerating the development and commercialization of innovative cardiovascular interventional products around the world.
The SELUTION SLRTM Drug-Eluting Balloon is not approved for sale in every country. Please contact your local representative for additional information


Need Help?
We’re here with the support and information to help you make the right decision for your patients.